|
US6653341B1
(en)
*
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
EP1087960B1
(en)
*
|
1998-06-17 |
2011-03-23 |
Eisai R&D Management Co., Ltd. |
Macrocyclic analogs and methods of their use and preparation
|
|
US8097648B2
(en)
*
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
DE10037310A1
(de)
|
2000-07-28 |
2002-02-07 |
Asta Medica Ag |
Neue Indolderivate und deren Verwendung als Arzneimittel
|
|
WO2003072754A2
(en)
*
|
2002-02-27 |
2003-09-04 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
|
|
AU2003228354B8
(en)
|
2002-03-22 |
2010-03-04 |
Eisai R&D Management Co., Ltd. |
Hemiasterlin derivatives and uses thereof in the treatment of cancer
|
|
US20050075395A1
(en)
*
|
2003-05-28 |
2005-04-07 |
Gary Gordon |
Continuous dosing regimen
|
|
JP2007500240A
(ja)
*
|
2003-05-29 |
2007-01-11 |
アボット・ラボラトリーズ |
Ａｂｔ−７５１による持続投与レジメン
|
|
WO2005011589A2
(en)
*
|
2003-07-29 |
2005-02-10 |
Eisai Co., Ltd. |
Drug delivery methods and devices
|
|
CN109180615A
(zh)
*
|
2004-06-03 |
2019-01-11 |
卫材R&D管理有限公司 |
用于制备软海绵素b的类似物的中间体
|
|
EP3587408A1
(en)
|
2004-06-03 |
2020-01-01 |
Eisai R&D Management Co., Ltd. |
Intermediates for the preparation of halichondrin b
|
|
US20060045846A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Horstmann Thomas E |
Reagents and methods for labeling terminal olefins
|
|
JP2008522623A
(ja)
*
|
2004-12-09 |
2008-07-03 |
エーザイ株式会社 |
ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
|
|
CN104311571B
(zh)
*
|
2007-10-03 |
2019-07-02 |
卫材R&D管理有限公司 |
用于合成软海绵素b类似物的中间体和方法
|
|
RU2517167C2
(ru)
*
|
2008-04-04 |
2014-05-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Аналоги галихондрина в
|
|
RU2476216C1
(ru)
*
|
2009-03-30 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Липосомальная композиция
|
|
JP5622719B2
(ja)
|
2009-03-30 |
2014-11-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
リポソーム組成物の製造方法
|
|
PL2415470T3
(pl)
|
2009-03-30 |
2016-12-30 |
|
Kompozycja liposomowa
|
|
EP2420504B1
(en)
*
|
2009-04-14 |
2014-01-15 |
Nissan Chemical Industries, Ltd. |
Method for producing tetrahydropyran compound and intermediate thereof
|
|
CA2787919C
(en)
|
2010-01-26 |
2018-07-31 |
Eisai R&D Management Co., Ltd. |
Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
|
|
SG10201602147YA
(en)
|
2011-03-18 |
2016-05-30 |
Eisai R&D Man Co Ltd |
Methods And Compositions For Predicting Response To Eribulin
|
|
WO2012147900A1
(en)
|
2011-04-28 |
2012-11-01 |
Eisai R&D Management Co., Ltd. |
Microreactor process for halichondrin b analog synthesis
|
|
EP2714937B1
(en)
|
2011-06-03 |
2018-11-14 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
CN104053645A
(zh)
|
2011-11-30 |
2014-09-17 |
阿方拉研究股份有限公司 |
用于制备(3r)-2,4-二-离去基团-3-甲基丁-1-烯的工艺
|
|
JP2015501818A
(ja)
|
2011-12-16 |
2015-01-19 |
アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． |
３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
|
|
CN104080793B
(zh)
*
|
2011-12-29 |
2017-09-19 |
阿方拉研究股份有限公司 |
2‑((2s,3s,4r,5r)‑5‑((s)‑3‑氨基‑2‑羟基丙‑1‑基)‑4‑甲氧基‑3‑(苯磺酰甲基)四氢呋喃‑2‑基)乙醛衍生物以及它们的制备方法
|
|
AU2013239290B2
(en)
|
2012-03-30 |
2017-08-03 |
Sandoz Ag |
Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein
|
|
MX2015007185A
(es)
|
2012-12-04 |
2017-09-05 |
Eisai R&D Man Co Ltd |
Uso de eribulina en el tratamiento de cancer de pecho.
|
|
EP2997017B1
(en)
|
2013-05-15 |
2017-08-09 |
Alphora Research Inc. |
3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
|
|
RU2672585C2
(ru)
|
2013-06-26 |
2018-11-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
|
|
JP6511613B2
(ja)
*
|
2013-07-03 |
2019-05-15 |
サンド・アクチエンゲゼルシヤフト |
ハリコンドリンＢの大環状Ｃ１−ケト類似体の製造のための合成方法及び該方法に有用な中間体、例えば−ＳＯ２−（ｐ−トリル）基を含有する中間体
|
|
CN103483352A
(zh)
*
|
2013-10-18 |
2014-01-01 |
李友香 |
抗肿瘤的药用原料药
|
|
JP6625533B2
(ja)
|
2013-11-04 |
2019-12-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ハリコンドリンｂの類縁体の合成において有用な大環化反応および中間体
|
|
BR112016012237B1
(pt)
|
2013-12-06 |
2023-02-07 |
Eisai R&D Management Co., Ltd |
Métodos úteis na síntese de análogos de halicondrina b
|
|
CN104860978A
(zh)
*
|
2014-02-20 |
2015-08-26 |
正大天晴药业集团股份有限公司 |
软海绵素b类似物的合成中间体
|
|
TW201617326A
(zh)
|
2014-03-06 |
2016-05-16 |
Ａｌｐｈｏｒａ研發股份有限公司 |
（ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
|
|
EP3148526B1
(en)
*
|
2014-05-28 |
2021-01-06 |
Eisai R&D Management Co., Ltd. |
Use of eribulin in the treatment of cancer
|
|
US10556910B2
(en)
*
|
2014-06-30 |
2020-02-11 |
President And Fellows Of Harvard College |
Synthesis of halichondrin analogs and uses thereof
|
|
ES2926687T3
(es)
|
2014-08-28 |
2022-10-27 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y método para su producción
|
|
US10208058B2
(en)
*
|
2014-09-09 |
2019-02-19 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
|
|
CN105713031B
(zh)
*
|
2014-12-05 |
2021-05-07 |
正大天晴药业集团股份有限公司 |
一种用于制备艾日布林的中间体及其制备方法
|
|
US20180028662A1
(en)
|
2015-02-25 |
2018-02-01 |
Eisai R&D Management Co., Ltd. |
Method for Suppressing Bitterness of Quinoline Derivative
|
|
KR20170122810A
(ko)
*
|
2015-03-04 |
2017-11-06 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
|
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
WO2016176560A1
(en)
|
2015-04-30 |
2016-11-03 |
President And Fellows Of Harvard College |
Chromium-mediated coupling and application to the synthesis of halichondrins
|
|
US10308661B2
(en)
*
|
2015-05-07 |
2019-06-04 |
Eisai R&D Management Co., Ltd. |
Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
|
|
WO2016182850A1
(en)
|
2015-05-08 |
2016-11-17 |
Albany Molecular Research, Inc. |
Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
|
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
|
JP6786610B2
(ja)
*
|
2016-02-12 |
2020-11-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
エリブリンの合成における中間体および関連する合成方法
|
|
WO2017188350A1
(ja)
|
2016-04-28 |
2017-11-02 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍の成長を抑制する方法
|
|
EP3464297B1
(en)
*
|
2016-05-26 |
2023-10-25 |
Dr. Reddy's Laboratories Ltd. |
Process for preparation of eribulin and intermediates thereof
|
|
US11136335B2
(en)
|
2016-06-30 |
2021-10-05 |
Eisai R&D Management Co., Ltd. |
Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
|
|
US20190263927A1
(en)
|
2016-10-14 |
2019-08-29 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
|
JP6978758B2
(ja)
|
2016-11-11 |
2021-12-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
パラジウム媒介ケトール化
|
|
WO2018096478A2
(en)
|
2016-11-23 |
2018-05-31 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
|
KR101991710B1
(ko)
|
2017-12-14 |
2019-06-21 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
KR101880939B1
(ko)
|
2017-01-02 |
2018-08-17 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
US10865212B2
(en)
|
2017-01-02 |
2020-12-15 |
Yonsung Fine Chemical Co.. Ltd. |
Intermediate for preparing eribulin mesylate and process for preparing the same
|
|
CN108341828B
(zh)
*
|
2017-01-24 |
2021-04-06 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
|
CN108341738B
(zh)
*
|
2017-01-24 |
2022-10-21 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
|
US9938288B1
(en)
|
2017-04-05 |
2018-04-10 |
President And Fellows Of Harvard College |
Macrocyclic compound and uses thereof
|
|
TWI836643B
(zh)
|
2017-04-05 |
2024-03-21 |
哈佛大學校長及研究員協會 |
巨環化合物及其用途
|
|
US11498892B2
(en)
|
2017-07-06 |
2022-11-15 |
President And Fellows Of Harvard College |
Fe/Cu-mediated ketone synthesis
|
|
HUE061306T2
(hu)
|
2017-07-06 |
2023-06-28 |
Harvard College |
Halikondrinok szintézise
|
|
US20190046513A1
(en)
|
2017-08-10 |
2019-02-14 |
Huya Bioscience International, Llc |
Combination therapies of hdac inhibitors and tubulin inhibitors
|
|
CN109694379B
(zh)
*
|
2017-10-24 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的中间体及其制备方法
|
|
EP3712141B1
(en)
|
2017-11-09 |
2023-07-12 |
Yonsung Fine Chemical Co., Ltd. |
Intermediate for preparing eribulin mesylate and method for preparing same
|
|
EP4403560A3
(en)
|
2017-11-15 |
2024-10-23 |
President And Fellows Of Harvard College |
Macrocyclic compounds and uses thereof
|
|
US11419856B2
(en)
|
2017-11-20 |
2022-08-23 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
|
US11008296B2
(en)
|
2017-11-21 |
2021-05-18 |
Natco Pharma Limited |
Intermediates for the preparation of eribulin thereof
|
|
US11542269B2
(en)
|
2018-01-03 |
2023-01-03 |
Eisai R&D Management Co., Ltd. |
Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
|
|
WO2019211877A1
(en)
|
2018-05-03 |
2019-11-07 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin b
|
|
WO2020008382A1
(en)
*
|
2018-07-04 |
2020-01-09 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
|
WO2020016847A2
(en)
*
|
2018-07-20 |
2020-01-23 |
Dr. Reddy’S Laboratories Limited |
Purification process for preparation of eribulin and intermediates thereof
|
|
CN113166096A
(zh)
*
|
2018-10-09 |
2021-07-23 |
雷迪博士实验室有限公司 |
制备艾立布林的方法及其中间体
|
|
US11447499B2
(en)
|
2019-06-14 |
2022-09-20 |
Rk Pharma Inc. |
Process for the preparation of eribulin mesylate intermediate
|
|
WO2020255164A1
(en)
|
2019-06-21 |
2020-12-24 |
Council Of Scientific And Industrial Research |
A chemo-enzymatic process for the preparation of homopropargylic alcohol
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
MX2022005221A
(es)
|
2019-11-07 |
2022-06-08 |
Eisai R&D Man Co Ltd |
Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso.
|
|
CN113135876B
(zh)
*
|
2020-01-16 |
2024-05-17 |
南通诺泰生物医药技术有限公司 |
艾日布林及其中间体的制备方法
|
|
MX2022009044A
(es)
*
|
2020-01-22 |
2022-08-11 |
Shanghai Senhui Medicine Co Ltd |
Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
|
|
KR102377262B1
(ko)
|
2020-05-11 |
2022-03-22 |
연성정밀화학(주) |
결정성 에리불린 염
|
|
IL279168B
(en)
*
|
2020-12-02 |
2022-04-01 |
Finetech Pharmaceutical Ltd |
A process for the preparation of eribulin
|
|
CN113354659B
(zh)
|
2021-06-08 |
2022-04-08 |
江苏慧聚药业股份有限公司 |
甲磺酸艾日布林的合成
|
|
MX2024000893A
(es)
*
|
2021-07-22 |
2024-02-06 |
Shanghai Senhui Medicine Co Ltd |
Farmaco conjugado de un derivado de eribulina.
|
|
WO2023212746A2
(en)
*
|
2022-04-30 |
2023-11-02 |
William Marsh Rice University |
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
|
|
WO2024153123A1
(zh)
*
|
2023-01-17 |
2024-07-25 |
成都百利多特生物药业有限责任公司 |
一种艾日布林类药物的偶联物
|